Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of kalopanax saponin A in preparation of anti-candida albicans drugs, drug preparation of kalopanax saponin A, and drug preparation for diseases caused by candida albicans

A technology of Candida albicans and thorny saponins, applied in the field of biomedicine, can solve the problems of high toxicity and side effects, easy drug resistance, etc., and achieve the effects of good virulence, reduced virulence, and less drug resistance

Inactive Publication Date: 2019-11-05
XUZHOU MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the existing antifungal drugs have disadvantages such as easy drug resistance and high toxicity and side effects. Therefore, the development of new antifungal drugs is an effective means to effectively treat fungal infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kalopanax saponin A in preparation of anti-candida albicans drugs, drug preparation of kalopanax saponin A, and drug preparation for diseases caused by candida albicans
  • Application of kalopanax saponin A in preparation of anti-candida albicans drugs, drug preparation of kalopanax saponin A, and drug preparation for diseases caused by candida albicans
  • Application of kalopanax saponin A in preparation of anti-candida albicans drugs, drug preparation of kalopanax saponin A, and drug preparation for diseases caused by candida albicans

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1Effect of thorny barley saponin A on the cytotoxicity of Caenorhabditis elegans

[0024] 1. Test drug

[0025] Robinia saponin A: It is extracted from the plant Robinia by the laboratory of Xuzhou Medical University, and its purity is greater than 98% as detected by analytical liquid phase.

[0026] Amphotericin B: American Sigma Reagent Company.

[0027] Dimethyl sulfoxide: American Sigma Reagent Company.

[0028] Accurately weigh the thorny bark saponin A and amphotericin B, use dimethyl sulfoxide (DMSO) as a solvent to prepare a mother solution with a final concentration of 10 mg / mL, and store it at -20°C. During the experiment, it was ensured that the content of dimethyl sulfoxide in all treatment groups was not higher than 1%.

[0029] 2. Preparation of C. elegans

[0030] Wild-type Caenorhabditis elegans N2 (purchased from the American Nematode Genetics Center) was used to carry out the toxicity evaluation experiment of apricoside A. Inoculate the...

Embodiment 2

[0034] Embodiment 2Effects of Echinopsis saponin A on the proliferation of Candida albicans

[0035] 1. Preparation of Experimental Candida Strains

[0036] Candida albicans wild-type strain YEM30, clinical isolates of Candida tropicalis CT171221301, Candida glabrata CG171122302, and Candida parapsilosis CP18092240 were all isolated from clinical samples submitted for inspection by the Laboratory Department of the Affiliated Hospital of Xuzhou Medical University, and were identified and confirmed by instruments and chromogenic medium. Clinically isolated azole multidrug-resistant strains CA10 and CA148 were donated by the Laboratory Department of Qianfoshan Hospital.

[0037] The above bacterial strains are suspended in seed preservation solution (physiological saline containing 20% ​​glycerol), and stored at -80°C for a long time. Before the experiment, the bacterial strain was transferred to YPD solid medium (1% yeast extract powder, 2% peptone, 2% glucose, 2% agar) from th...

Embodiment 3

[0046] Embodiment 3Effect of romania saponin A on the virulence of Candida albicans

[0047] 1.Effect of roechoside A on the adhesion ability of Candida albicans

[0048] Dilute the YEM30 strain in the logarithmic growth phase to about 1×10 with RPMI1640 medium 6 cells / mL, add Erythroside A to the final concentrations of 2, 4, 8, and 16 μg / mL, respectively, and amphotericin B with a final concentration of 2 μg / mL was used as the positive control group, and the solvent DMSO with a final concentration of 1% was used as the negative control group , transfer 100 μL / well of each treatment group into a flat-bottomed 96-well plate, set up 4 parallel wells for each treatment group, incubate at 37°C for 90 minutes, discard the supernatant, wash the bottom of the plate three times with sterile PBS buffer, remove For non-adherent cells, the amount of cells adhered to the bottom of the well plate was detected with the XTT cell proliferation assay kit. The experimental results are shown ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of kalopanax saponin A in preparation of anti-candida albicans drugs, a drug preparation of kalopanax saponin A, and a drug preparation for diseases caused by candida albicans. The inhibition of the virulence of candida albicans is used as a breakthrough point, and the effect of low-toxic kalopanax saponin A not easily producing drug resistance on the adhesion, mycelium formation and envelope formation of candida albicans are targetedly evaluated and screened. The results indicate that the toxicity of the kalopanax saponin A to caenorhabditis elegans growth is relatively small, and the kalopanax saponin A itself is indicated to have low toxicity and do not affect the growth of human cells; the kalopanax saponin A can effectively reduce the adhesion ability, yeast-mycelium morphological transformation ability and envelope formation ability of candida albicans at a sub dose lower than the minimum bacteriostasis concentration, has a good effect of reducing pathogenicity of candida albicans and achieves the purpose of the invention not mainly by killing candida albicans, so the kalopanax saponin A does not easily produce drug resistance. The kalopanax saponin A has a good application prospect in the research and development of antifungal drugs, especially in the research and development of the anti-candida albicans drugs.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of romania saponin A in the preparation of anti-candida medicaments, its pharmaceutical preparations and the preparations for diseases caused by candida albicans. Background technique [0002] With the development of immunosuppressive therapy, the extensive use of broad-spectrum antibacterial drugs, and the wide application of retention devices, the incidence of fungal infection has increased year by year, and it has become one of the common clinical infectious diseases. Candida is the most common conditional pathogenic fungus in clinic, which can colonize the skin, mucous membrane, digestive tract, reproductive tract and other parts of healthy people. When the body's immune function declines and the flora becomes imbalanced, it can cause acute or chronic infections in various organs of the human body. Especially patients with impaired or deficient immune sys...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P31/10
CPCA61K31/704A61P31/10
Inventor 李颖朱作斌顾兵单明珠么焕开李洪春陈莹
Owner XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com